GB202115156D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB202115156D0
GB202115156D0 GBGB2115156.8A GB202115156A GB202115156D0 GB 202115156 D0 GB202115156 D0 GB 202115156D0 GB 202115156 A GB202115156 A GB 202115156A GB 202115156 D0 GB202115156 D0 GB 202115156D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2115156.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artios Pharma Ltd
Original Assignee
Artios Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artios Pharma Ltd filed Critical Artios Pharma Ltd
Priority to GBGB2115156.8A priority Critical patent/GB202115156D0/en
Publication of GB202115156D0 publication Critical patent/GB202115156D0/en
Priority to EP22802224.0A priority patent/EP4419527A1/en
Priority to TW111140009A priority patent/TW202334150A/zh
Priority to IL311922A priority patent/IL311922A/en
Priority to SM20250123T priority patent/SMT202500123T1/it
Priority to CN202280070670.3A priority patent/CN118234728A/zh
Priority to MX2024004874A priority patent/MX2024004874A/es
Priority to CA3233255A priority patent/CA3233255A1/en
Priority to PL22797829.3T priority patent/PL4419526T3/pl
Priority to RS20250272A priority patent/RS66620B1/sr
Priority to HUE22797829A priority patent/HUE070568T2/hu
Priority to JP2024523445A priority patent/JP2024542949A/ja
Priority to AU2022374050A priority patent/AU2022374050A1/en
Priority to DK22797829.3T priority patent/DK4419526T3/da
Priority to PCT/GB2022/052690 priority patent/WO2023067356A1/en
Priority to LTEPPCT/GB2022/052690T priority patent/LT4419526T/lt
Priority to HRP20250334TT priority patent/HRP20250334T1/hr
Priority to JP2024523601A priority patent/JP2024539132A/ja
Priority to KR1020247015701A priority patent/KR20240099274A/ko
Priority to US18/699,286 priority patent/US20240425511A1/en
Priority to US18/701,963 priority patent/US20260124214A1/en
Priority to FIEP22797829.3T priority patent/FI4419526T3/fi
Priority to CN202280083817.2A priority patent/CN119053600A/zh
Priority to EP22797829.3A priority patent/EP4419526B1/en
Priority to PT227978293T priority patent/PT4419526T/pt
Priority to ARP220102871A priority patent/AR127431A1/es
Priority to SI202230104T priority patent/SI4419526T1/sl
Priority to ES22797829T priority patent/ES3008687T3/es
Priority to PCT/GB2022/052689 priority patent/WO2023067355A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2115156.8A 2021-10-21 2021-10-21 Novel compounds Ceased GB202115156D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds
PCT/GB2022/052689 WO2023067355A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
PCT/GB2022/052690 WO2023067356A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
LTEPPCT/GB2022/052690T LT4419526T (lt) 2021-10-21 2022-10-21 Heterocikliniai junginiai, skirti vėžiui gydyti
IL311922A IL311922A (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in cancer treatment
SM20250123T SMT202500123T1 (it) 2021-10-21 2022-10-21 Composti eterociclici per uso nel trattamento del cancro
CN202280070670.3A CN118234728A (zh) 2021-10-21 2022-10-21 用于治疗癌症的杂环化合物
MX2024004874A MX2024004874A (es) 2021-10-21 2022-10-21 Compuestos heterociclicos para uso en el tratamiento de cancer.
CA3233255A CA3233255A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
PL22797829.3T PL4419526T3 (pl) 2021-10-21 2022-10-21 Związki heterocykliczne do stosowania w leczeniu nowotworu
RS20250272A RS66620B1 (sr) 2021-10-21 2022-10-21 Heterociklična jedinjenja za upotrebu u lečenju kancera
HUE22797829A HUE070568T2 (hu) 2021-10-21 2022-10-21 Heterociklusos vegyületek rák kezelésében való alkalmazásra
JP2024523445A JP2024542949A (ja) 2021-10-21 2022-10-21 がん治療での使用のためのヘテロ環式化合物
AU2022374050A AU2022374050A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
DK22797829.3T DK4419526T3 (da) 2021-10-21 2022-10-21 Heterocykliske forbindelser til anvendelse i behandlingen af cancer
EP22802224.0A EP4419527A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
JP2024523601A JP2024539132A (ja) 2021-10-21 2022-10-21 がんの治療における使用のためのヘテロ環式化合物
US18/701,963 US20260124214A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
HRP20250334TT HRP20250334T1 (hr) 2021-10-21 2022-10-21 Heterociklički spojevi za uporabu u liječenju raka
KR1020247015701A KR20240099274A (ko) 2021-10-21 2022-10-21 암의 치료에의 사용을 위한 헤테로사이클릭 화합물
US18/699,286 US20240425511A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
TW111140009A TW202334150A (zh) 2021-10-21 2022-10-21 新穎化合物
FIEP22797829.3T FI4419526T3 (fi) 2021-10-21 2022-10-21 Heterosyklisiä yhdisteitä käytettäväksi syövän hoidossa
CN202280083817.2A CN119053600A (zh) 2021-10-21 2022-10-21 用于治疗癌症的杂环化合物
EP22797829.3A EP4419526B1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer
PT227978293T PT4419526T (pt) 2021-10-21 2022-10-21 Compostos heterocíclicos para utilização no tratamento de cancro
ARP220102871A AR127431A1 (es) 2021-10-21 2022-10-21 Compuestos novedosos
SI202230104T SI4419526T1 (sl) 2021-10-21 2022-10-21 Heterociklične spojine za uporabo pri zdravljenju raka
ES22797829T ES3008687T3 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds

Publications (1)

Publication Number Publication Date
GB202115156D0 true GB202115156D0 (en) 2021-12-08

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2115156.8A Ceased GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds

Country Status (24)

Country Link
US (2) US20240425511A1 (cg-RX-API-DMAC7.html)
EP (2) EP4419527A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024539132A (cg-RX-API-DMAC7.html)
KR (1) KR20240099274A (cg-RX-API-DMAC7.html)
CN (2) CN119053600A (cg-RX-API-DMAC7.html)
AR (1) AR127431A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022374050A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233255A1 (cg-RX-API-DMAC7.html)
DK (1) DK4419526T3 (cg-RX-API-DMAC7.html)
ES (1) ES3008687T3 (cg-RX-API-DMAC7.html)
FI (1) FI4419526T3 (cg-RX-API-DMAC7.html)
GB (1) GB202115156D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250334T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070568T2 (cg-RX-API-DMAC7.html)
IL (1) IL311922A (cg-RX-API-DMAC7.html)
LT (1) LT4419526T (cg-RX-API-DMAC7.html)
MX (1) MX2024004874A (cg-RX-API-DMAC7.html)
PL (1) PL4419526T3 (cg-RX-API-DMAC7.html)
PT (1) PT4419526T (cg-RX-API-DMAC7.html)
RS (1) RS66620B1 (cg-RX-API-DMAC7.html)
SI (1) SI4419526T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500123T1 (cg-RX-API-DMAC7.html)
TW (1) TW202334150A (cg-RX-API-DMAC7.html)
WO (2) WO2023067355A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10760081B2 (en) 2015-10-07 2020-09-01 New York University Compositions and methods for enhancing CRISPR activity by POLQ inhibition
EP4010080B1 (en) * 2019-08-09 2023-09-27 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115158D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115150D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds

Also Published As

Publication number Publication date
MX2024004874A (es) 2024-05-06
JP2024539132A (ja) 2024-10-28
CN118234728A (zh) 2024-06-21
SMT202500123T1 (it) 2025-05-12
EP4419526A1 (en) 2024-08-28
LT4419526T (lt) 2025-03-25
CN119053600A (zh) 2024-11-29
TW202334150A (zh) 2023-09-01
RS66620B1 (sr) 2025-04-30
AU2022374050A1 (en) 2024-05-02
JP2024542949A (ja) 2024-11-19
WO2023067356A1 (en) 2023-04-27
PL4419526T3 (pl) 2025-04-22
US20240425511A1 (en) 2024-12-26
EP4419526B1 (en) 2024-12-25
EP4419527A1 (en) 2024-08-28
HUE070568T2 (hu) 2025-06-28
WO2023067355A1 (en) 2023-04-27
KR20240099274A (ko) 2024-06-28
ES3008687T3 (en) 2025-03-24
CA3233255A1 (en) 2023-04-27
SI4419526T1 (sl) 2025-05-30
DK4419526T3 (da) 2025-02-17
PT4419526T (pt) 2025-02-03
US20260124214A1 (en) 2026-05-07
FI4419526T3 (fi) 2025-02-13
AR127431A1 (es) 2024-01-24
HRP20250334T1 (hr) 2025-06-06
IL311922A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
GB201905375D0 (en) Novel compounds
GB2637108B (en) Novel Compounds
GB202115158D0 (en) Novel compounds
GB202013728D0 (en) Novel compounds
GB202016800D0 (en) Novel compounds
GB202008749D0 (en) Novel compounds
GB202115150D0 (en) Novel compounds
GB2605894B (en) Novel compounds
GB202101734D0 (en) Novel Compounds
GB202106872D0 (en) Novel compounds
GB202106871D0 (en) Novel compounds
GB202014341D0 (en) Novel compounds
GB202118096D0 (en) Novel compounds
GB202117366D0 (en) Novel compounds
GB202113016D0 (en) Novel compounds
GB202110809D0 (en) Novel compounds
GB202109446D0 (en) Novel compounds
GB202108873D0 (en) Novel compounds
GB202101935D0 (en) Novel compounds
GB202101573D0 (en) Novel compounds
GB202101280D0 (en) Novel compounds
GB202019590D0 (en) Novel Compounds
GB202019588D0 (en) Novel Compounds
GB202016785D0 (en) Novel compounds
GB202016791D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)